益生菌治疗腹泻型肠易激综合征  

A clinical trail of probiotics in the treatment of IBS-D

作　　者：朱丽明[1] 柯美云[1] 周丽雅[2] 袁耀宗[3] 罗金燕[4] 候晓华[5] 陈旻湖[6] 

机构地区：[1]中国医学科学院中国协和医科大学北京协和医院,北京100730 [2]北京大学第三医院,北京100083 [3]上海交通大学医学院附属瑞金医院,上海200025 [4]西安交通大学第二医院,陕西西安710004 [5]华中科技大学同济医学院附属协和医院,湖北武汉430022 [6]广州中山大学附属第一医院,广东广州510080

出　　处：《基础医学与临床》2008年第10期1070-1074,共5页Basic and Clinical Medicine

摘　　要：目的评估枯草杆菌、屎肠球菌二联活菌胶囊(美常安)和双歧杆菌、乳酸杆菌、肠球菌三联活菌胶囊(培菲康)对腹泻型肠易激综合征(IBS-D)的疗效和安全性,以及对患者生活质量的影响。方法符合罗马II诊断标准的IBS-D患者158例,男性101例,女性57例,平均年龄(44±12)岁;随机分两组,分别给予美常安和培菲康2粒3/d2周,记录腹痛、腹胀、大便频率、大便性状、排便急迫症状计分、生活质量评分;治疗结束后继续随访一周,观察记录不良反应。结果两组基线期病程、症状具有可比性;治疗后单项症状计分和总症状计分均明显下降(P<0.05);治疗1周总有效率分别为41.8%(33/79)和49.6%(39/79),2周总有效率分别为51.9%(41/79)和65.8%(52/79);生活质量影响评分从33.12±23.11和31.88±20.17下降至18.06±18.73和19.93±17.43(P<0.01);不良反应少而且轻微。结论美常安和培菲康可以减轻IBS-D的症状,改善患者生活质量。Objective To evaluate the efficacy and safety of Medilac-S （Bacillus subtilis and Enterococcus faecium） and BIFICO （Bifidobacterium longum, lactobacillus acidophilus, Enterococcus fecalis） and to assess the therapy on life quality （QOL） of patients with IBS-D. Methods One hundred and fifty eight patients with IBS-D fulfilling Rome Ⅱ criteria were enrolled into study. Following one week screening, patients were randomly allocated to receive either Medilac-S or Bifico 2 tab. tid for two weeks and then followed up for one more week. Symptoms were recorded, including abdominal pain and bloating, frequency of defecation, form of stools, and the sensation df urgency evacuation. QOL was surveyed by questionnaire. Results One hundred and fifty eight patients （ 101 male and 57 female, mean age 44 ± 12 years） concluded the study. The course of disease and symptom severity in two groups were comparable at baseline. Each symptom score and total symptoms score were decreased significantly after treatment in both groups （P 〈0.05）. The total effective rate was 41.8% and 49.6% by the end of 1-week and 51.9% and 65.8% by the end of second week. QOL reduced from 33.12 ±23.11 to 18.06 ± 18.73 and 31.88 ±20. 17 to 19.93 ±17.43, respectively（P 〈0. 01 ）. No severe adverse events occurred and a few cases （3/79 and 4/79） of mild adverse events have been recorded. Conclusion Medilac-S and Bifico alleviated the symptoms of IBS-D and improved the QOL. They are proved to be effective and safe therapy for IBS-D.

关 键 词：益生菌 腹泻型肠易激综合征 生活质量 

分 类 号：R574.4[医药卫生—消化系统]